1 discussing the validity of a new classifi cation scheme for pneumonia, including for health-care-associated pneumonia (HCAP). The investigators reviewed the available evidence, including our 2009 study. 2 They conclude that this study does not prove much more than that patients admitted to hospital within 180 days have a similar mortality as patients with hospital-acquired pneumonia, and that the key issue of HCAP-excess mortality due to drug-resistant pathogens-was not assessed. Here we present microbiological data from this prospective study, which was undertaken in Italy between January and July, 2007.
Microbiological data were culture results from the fi rst 5 days after admission to hospital, or within 5 days of diagnosis with pneumonia. An aetiological diagnosis was defi nitive if one of the following criteria were met: (1) blood cultures yielded a bacterial pathogen (in the absence of an apparent extrapulmonary focus); (2) pleural fl uid and cultures of transthoracic needle aspiration yielded a bacterial pathogen; (3) a respiratory sample that was representative of the lower respiratory tract (fi beroptic bronchoscopy with protected catheter) yielded a bacterial pathogen; (4) isolation of Legionella pneumophila in sputum, or detection of L pneumophila serogroup 1 or pneumococcal antigen in urine; (5) an increase of four times in the antibody titre, or seroconversion for atypical pathogens. An aetiological diagnosis was regarded as presumptive when a predominant microorganism was isolated from a purulent sample (more than 25 polymorphonuclear leucocytes and fewer than ten squamous cells per low-power fi eld [original magnifi cation×10]) with compatible fi ndings from Gram stains.
Overall, an aetiological diagnosis was obtained in 22·4% of patients (95% CI 20·2-24·6). 28·4% (23·4-33·4) had a presumptive microbiological diagnosis, and 71·6% (66·6-77·6) a defi nitive diagnosis. Bacteraemia occurred in six patients with HCAP (Streptococcus pneumoniae in two, Staphylococcus aureus in three, and Escherichia coli in one), in four patients with hospital-acquired pneumonia (S aureus in three, and E coli in one), and in seven patients with communityacquired pneumonia (S pneumoniae in four, E coli in two, and Pseudonomas aeruginosa in one). No statistically signifi cant diff erences were noted in the rates of bacteraemia between the three groups. A microbiological documentation was more frequently obtained in patients with HCAP (31·1%, 95% CI 19·7-42·5) than in those with community-acquired (18·4, 11·9-24·8) or hospital-acquired pneumonia (24·5, 9·2-39·8).
The distribution of pathogens varied among the three pneumonia categories (table), with S aureus predominating in the HCAP and hospital-acquired pneumonia groups, and S pneumoniae in the communityacquired group. The rate of meticillin resistance among S aureus isolates was 37·5% in the community-acquired group, 63·6% in the HCAP group, and 50% in the hospital-acquired group. These results seem to confi rm the role of potentially multidrug resistant pathogens such as S aureus, P aeruginosa, and other Gram-negative bacilli, in patients with HCAP. As noted by other investigators, [3] [4] [5] patients with HCAP have a higher incidence of multidrug-resistant bacteria and, consequently, an increased likelihood of receiving inappropriate antibacterial therapy at the start. 2 This factor seems to be crucial in explaining the increased mortality recorded for HCAP.
In our study, features of patients with community-acquired pneumonia and HCAP were not substantially diff erent in terms of median age, presence of comorbidities, or immunosuppression. Thus, the proposed classifi cation of community-acquired pneumonia based on mean age or functional status is questionable. The review by Ewig and colleagues underestimates the value of clinical and microbiological studies undertaken in diff erent areas of the world (Europe, Japan, and the USA). Future prospective clinical trials are needed to delineate the pathogens and risk factors associated with HCAP. However, the available evidence supports HCAP as a new category of pneumonia, which is distinct from community-acquired CAP n=41 HCAP n=28
HAP n=12 p value

Staphylooccus aureus
7 (17·1%) 11 (39·3%) 6 (50·0%) 0·034
Streptococcus pneumoniae 18 (43·9%) 2 (7·1%) 0 <0·001
Gram-negative bacteria
Pseudonomas aeruginosa 4 (9·7%) 2 (7·1%) 2 (16·7%) 0·65
Enterobacteriaceae and other Gram negative bacilli 5 (12·2%) 9 (32·1%) 2 (16·7%) 0·11
Haemophilus infl uenzae/parainfl uenzae 1 (2·4%) 1 (3·6%) 1 (8·3%) 0·68
Atypical bacteria
Mycoplasma, Chlamydia, Legionella spp 3 (7·3%) 1 (3·6%) 1 (8·3%) 0·77
Data are number (%) of patients. CAP=community-acquired pneumonia. HCAP=health-care-associated pneumonia. HAP=hospital-acquired pneumonia. *CAP: one atypical mycobacterium, one Aspergillus fumigatus, and one Mycobacterium tuberculosis; †HCAP: one atypical mycobacterium, one M tuberculosis. immediately. Moreover, caution should be taken when results of MRSA cultures are interpreted. In the absence of quantitative cultures, only bacteraemic episodes, or positive cultures from sites that are normally sterile, would be defi nite evidence for infection. Pseudomonas aeruginosa was even slightly higher in communityacquired than in hospital-acquired pneumonia (9·7% vs 7·1%), and Gram-negative enterobacteriaceae were more frequent in HCAP than in hospital-acquired pneumonia (32·1 vs 16·7). The unusually high rates of P aeruginosa and Gramnegative enteric bacilli in communityacquired pneumonia add to our reservations about the validity of the microbiological data. The investigators do not provide data for resistance patterns of P aeruginosa and Gram-negative enteric bacilli; we cannot therefore know the true rate of multidrug-resistant pathogens, although they claim to have identifi ed an excessive rate of multidrug resistance in patients meeting the defi nition for HCAP.
Venditti and colleagues try to convince us that HCAP is diff erent from community-acquired pneumonia with just 22 patients (11 with MRSA, two with P aeruginosa, nine with pneumonia, both epidemiologically and microbiologically.
